Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 1, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
Gestational Trophoblastic Neoplasia
Interventions
DRUG

Dostarlimab

First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Miami

OTHER

NCT05405192 - Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | Biotech Hunter | Biotech Hunter